Nanostics is a clinical-stage precision health company developing novel and minimally invasive predictive risk stratification models to bring clarity to healthcare decisions.

We designed a novel liquid biopsy platform technology called ClarityDX® that combines highly sensitive biomarker (including biomarkers on extracellular vesicles) detection with advanced machine learning algorithms to predict the risk of diseases from any fluid in the body.

There’s a lot riding on
your prostate health…

KNOW THE SCORE.

ClarityDX Prostate uses clinical and blood-based biomarkers to help quantify a patient’s risk of having aggressive prostate cancer helping patients and their healthcare providers make more informed healthcare decisions.

Our bodies use tiny messengers called extracellular vesicles to communicate throughout the body. At Nanostics our novel platform technology deciphers these messages to better diagnose disease. We’re validating a new test that accurately diagnoses clinically significant prostate cancer from a few drops of blood.

Dr. John Lewis
Dr. John LewisCEO of Nanostics

Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.